UK’s FTSE 100 closes at seven-week high on fiscal reassurance, defensive buying

The FTSE 100 rose 1.1% to 10,840.35, a seven-week high, as investors rotated toward defensive large caps amid a global AI-related chip selloff; the FTSE 250 gained 0.26%. AstraZeneca and GSK advanced 3.2% and 2.9%, while THG surged 16.3% after raising its annual profit forecast; Mondi fell 7.9% and Antofagasta dropped 4.1%. August UK GDP grew 0.1% versus expectations for a 0.1% decline, and officials reiterated fiscal discipline while the BoE’s chief economist cautioned that a future rate increase would not necessarily signal a prolonged series of hikes.

Analysis

Rotation, not a clean risk-off signal. The move favors cash-generative defensives over AI-sensitive cyclicals, but the rate backdrop is internally conflicted: lower yields can support defensive equity multiples, while persistent inflation and a possible Bank of England hike would pressure long-duration valuations. A quick reversal in yields could therefore unwind the relative move even if the technology selloff persists. The FTSE’s resilience should not be read as proof of improving UK domestic demand; the reported GDP growth was marginal and does not establish a durable consumption recovery.

Over the next 1–3 months, AZN, GSK and UL could retain relative support if investors continue to reduce exposure to high-growth technology. That is a flow tailwind, not new evidence of earnings acceleration. Conversely, ANTO faces both a company-specific production headwind and copper-price sensitivity; a rebound in copper or production recovery could rapidly reverse its relative weakness. MNDI’s price increases may defend nominal revenue, but do not establish margin recovery if energy costs remain elevated or customers resist pricing. THG’s guidance upgrade is a company-specific positive; verify conversion into cash flow before treating it as a broader consumer signal.

Contrarian check: defensive positioning may already be crowded after the rotation. The key distinction is relative performance versus absolute upside: these names can outperform while still falling if rates rise or equities de-risk broadly. Reassess on BoE policy signals, yield direction, copper prices, and subsequent company guidance; this article alone does not establish a durable earnings trend.

Key Decisions for Investors

• Tactical relative-value watch: consider a small long AZN/GSK basket against ANTO only if the defensive-versus-cyclical rotation persists into the next sessions. Enter on continued relative strength rather than chasing the day’s move; cut or reassess if yields reverse higher, copper rebounds materially, or AZN/GSK underperform despite further technology weakness. This is a relative trade, not a claim that the pharma names have near-term earnings catalysts.
• Avoid adding outright ANTO exposure until the next production update clarifies whether the quarterly decline is temporary; monitor copper and company production guidance. A production recovery alongside firm copper would falsify the negative near-term setup.
• Treat MNDI’s pricing action as an alert, not proof of margin improvement. Check whether subsequent results show price realization offsetting energy costs and whether volumes hold; persistent cost pressure or weaker volumes would undermine the recovery case.
• Do not extrapolate THG’s forecast increase without cash-conversion evidence. Revisit after results or an update on cash flow; failure to convert the higher profit outlook into cash would weaken the positive signal.